Dashboard
Manage Tickers

GRFSGrifols SA

Nasdaq grifols.com


$ 7.06 $ 0.10 (1.44 %)    

Friday, 16-Aug-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 475.24 $ 0.61 (0.13 %)
DIA $ 406.80 $ 0.86 (0.21 %)
SPY $ 554.24 $ 1.24 (0.22 %)
TLT $ 97.41 $ 0.34 (0.35 %)
GLD $ 231.90 $ 5.08 (2.24 %)
$ 7.06
$ 7.05 x 300
-- x --
-- - --
$ 5.30 - $ 12.15
1,090,183
na
4.85B
$ 0.85
$ 14.53
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

grifols-gigagen-receives-fda-clearance-of-ind-application-for-phase-1-trial-of-recombinant-polyclonal-for-hbv-treatment-giga-2339
Grifols' GigaGen Receives FDA Clearance Of...
07/31/2024 12:10:09

GIGA-2339 is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic hepatitis B vir...

grifols-new-auditor-discovers-non-cash-accounting-discrepancy-linked-to-china-stake-spanish-company-to-report-adjustment-related-to-china-stake-discrepancy-in-reserves-accounting-found-by-auditor-deloitte---bloomberg-news
"Grifols' New Auditor Discovers Non-Cash A...
07/30/2024 12:24:02

https://www.bloomberg.com/news/articles/2024-07-30/grifols-new-auditor-finds-non-cash-accounting-discrepancy-linked-to-china-st...

fda-approves-expanded-label-for-grifols-xembify-the-first-20-scig-for-treatment-nave-patients-with-primary-humoral-immunodeficiencies-approval-includes-biweekly-dosing-following-positive-phase-4-data-enhancing-flexibility-and-convenience-for-patients
FDA Approves Expanded Label For Grifols' X...
07/29/2024 12:01:37

grifols-board-votes-to-grant-brookfield-access-to-information-for-potential-takeover-bid-establishes-independent-committee-to-monitor-transaction-progress-and-present-proposals-to-board
Grifols Board Votes To Grant Brookfield Ac...
07/12/2024 16:54:14

- Reuters 

why-arhaus-shares-are-trading-lower-by-around-8-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Arhaus Shares Are Trading Lower By Aro...
07/08/2024 17:16:55

beleaguered-spanish-drug-firm-grifols-stock-jumps-on-monday---heres-why
Beleaguered Spanish Drug Firm Grifols Stoc...
07/08/2024 15:16:46

Grifols reveals Brookfield Capital's preliminary discussions with major shareholders about a potential joint bid to delist ...

corning-increases-sales-forecast-joins-morphic-holding-lucid-group-and-other-big-stocks-moving-higher-on-monday
Corning Increases Sales Forecast, Joins Mo...
07/08/2024 14:19:23

Core News & Articles
Market-Moving News for July 8th
07/08/2024 12:38:38

GRFS: 31% | Brookfield Confirms It Held Exploratory Discussions With Certain Reference Shareholders Of Co In Relation To A Pote...

brookfield-confirms-it-held-exploratory-discussions-with-certain-reference-shareholders-of-co-in-relation-to-a-potential-joint-offer-for-grifols-shares-to-delist-them
Brookfield Confirms It Held Exploratory Di...
07/08/2024 09:48:09

In relation to certain rumors appearing in the media about a potential transaction involving Grifols, S.A. ("Grifols" o...

why-paramount-global-shares-are-trading-higher-by-around-8-here-are-20-stocks-moving-premarket
Why Paramount Global Shares Are Trading Hi...
07/08/2024 09:40:41

grifolss-subsidiary-biotest-forecasts-approximately-1b-in-revenue-from-sales-in-the-us-of-its-intravenous-immunoglobulin-yimmugo-during-the-next-seven-years-following-recent-fda-approval-to-treat-primary-immunodeficiencies
Grifols's Subsidiary Biotest Forecasts App...
07/01/2024 10:09:58

Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in f...

grifols-says-at-end-june-2024-considering-sraas-proceeds-leverage-ratio-is-expected-to-reach-54x-vs-68x-in-march-2024-fcf-in-q2-2024-expected-to-be-positive-contributing-to-reach-5-million-fy24-guidance-which-includes-480-million-of-extraordinary-items-by-end-june-liquidity-will-stand-at-more-than-24-billion-including-sraas-proceeds-is-completely-separate-entity-from-scranton-and-none-of-scrantons-liabilities-are-consolidated-at-cos-group
Grifols Says At End June 2024, Considering...
06/27/2024 16:37:03

- Reuters

grifols-says-16-billion-net-cash-proceeds-from-sale-of-20-equity-stake-in-shanghai-raas-are-currently-deposited-in-cos-bank-account-proceeds-will-be-fully-allocated-to-reduce-2025-senior-secured-notes-and-2027-term-loan-b-and-on-a-pro-rata-basis-as-per-credit-agreement-to-repay-in-full-2025-debt-maturities-leaving-no-additional-maturities-until-2027
Grifols Says €1.6 Billion Net Cash Proceed...
06/27/2024 16:35:25

- Reuters 

levi-strauss-posts-mixed-results-joins-walgreens-aerovironment-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session
Levi Strauss Posts Mixed Results, Joins Wa...
06/27/2024 12:33:51

grifols-completes-20-equity-stake-sale-in-sraas-and-inks-partnership-with-haier-group
Grifols Completes 20% Equity Stake Sale In...
06/18/2024 11:37:38

grifols-shares-are-trading-higher-after-the-companys-biotest-received-fda-approval-for-yimmugo-immunoglobulin-to-treat-primary-immunodeficiencies
Grifols shares are trading higher after th...
06/17/2024 11:48:03

grifols-subsidiary-biotest-receives-fda-approval-for-yimmugo-an-intravenous-immunoglobulin-therapeutic-to-treat-primary-immunodeficiencies-with-us-launch-expected-in-second-part-of-2024
Grifols' Subsidiary Biotest Receives FDA A...
06/17/2024 08:26:40

With Biotest-developed Yimmugo, Grifols adds to its remarkable franchise of intravenous and subcutaneous immunoglobulins to m...

grifols-chairman-glanzmann-says-cfo-alfredo-arroyo-to-step-down-role-of-grifols-chairman-will-no-longer-be-executive
Grifols Chairman Glanzmann Says CFO Alfred...
05/14/2024 16:58:25

- Bloomberg

grifols-q1-net-revenues-163-billion-vs-156-billion-yoy-sees-q1-rd-negative-net-investment-905-million-vs-1047-million-yoy-currently-working-to-improve-fcf-guidance-in-light-of-several-ongoing-initiatives-to-hold-investor--analysts-day-on-oct-10
Grifols Q1 Net Revenues €1.63 Billion Vs €...
05/14/2024 15:47:16

- Reuters 

grifols-on-track-to-meet-fy-guidance-and-reduce-debt
Grifols On Track To Meet FY Guidance And R...
05/14/2024 15:39:59

- Reuters

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION